EUVIMEDEUVIMED entdecken
Open Access

Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India

Arya Pradhan, Harsha P Panchal

Cureus · 19.05.2026

DOI: 10.7759/cureus.109238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 19.05.2026. Verfasst von Arya Pradhan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

acalabrutinibbruton’s tyrosine kinase inhibitorschronic lymphocytic leukaemiaibrutiniblymphocytes

Autor:innen und Institutionen

  • Department of Medical Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND.

Zitieren

APA

Pradhan, A., & Panchal, H. P. (2026). Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. Cureus. https://doi.org/10.7759/cureus.109238

Vancouver

Pradhan A, Panchal HP. Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. Cureus. 2026. doi:10.7759/cureus.109238

BibTeX
@article{Pradhan2026,
  author = {Pradhan, Arya and Panchal, Harsha P},
  title = {Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.109238}
}
Kostenlos starten →